Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Cibus, Inc.NASDAQ: CBUS

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 652.02M shares rose 2707.7% year over year, ahead of the +1164.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 42.5% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2707.7% holds above the trailing-twelve-month pace of +1164.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
652.02M+42.5% QoQ
Last fiscal yearDec 2025
457.57M+1870.4% YoY
LTMMar 2026
301.04M+1164.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2707.7%——
1 year+1870.4%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
457.57M USD
Year-over-year change
+1870.4%
4-year CAGR
-5.7%

Weighted Avg Shares (Diluted) vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's LTM Mar 2026 weighted avg shares (diluted) of 301.04M shares is the highest of the 10 companies compared; the peer median is 52.9M shares.
  • Its year-over-year change of +1164.8% is the highest of 10, against a peer median of +55.6%.
  • Over three fiscal years its annual growth of -7.5% compares with a peer median of +15.4%.
CBUS Competitors Peer median
Weighted Avg Shares (Diluted) for CBUS and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.46M +14.7%-22.1%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1045.8%+372.5%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
MNOVMediciNova, Inc.LTM Mar 202649.09M +0.1%+0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
CAMPCAMP4 Therapeutics CorporationLTM Mar 202637.54M +102.0%—
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
Peer median (excluding CBUS) 52.9M+55.6%+15.4%

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.99M157K1.82M4.26M3.64M
Cost of Revenue28.56M1.53M395K05.92M
Gross Profit(2.57M)(1.38M)1.42M4.26M(2.28M)
Gross Margin-9.9%-877.1%78.3%100.0%-62.8%
Research & Development11.34M11.55M42.37M50.43M44.2M
Selling, General & Admin15.38M9.44M28.91M30.8M26.91M
Operating Expenses26.76M20.99M320.31M262.66M65.18M
Depreciation & Amortization2.34M1.53M4.69M6.86M5.92M
EBITDA(25.43M)(15.21M)(314.59M)(241.64M)(90.77M)
EBITDA Margin-97.9%-9687.9%-17313.4%-5669.5%-2494.3%
Operating Income(29.33M)(22.37M)(318.88M)(258.4M)(67.46M)
Operating Margin-112.9%-14248.4%-17550.0%-6062.8%-1853.9%
Interest Income17K60K527K631K438K
Interest Expense1.43M87K18.89M34.19M35.48M
Other Income / Expenses133K5.48M(18.76M)(24.29M)(64.71M)
Income Before Tax(29.2M)(16.89M)(337.64M)(282.68M)(132.17M)
Pre-Tax Margin-112.4%-10758.6%-18582.4%-6632.7%-3632.1%
Income Tax Expense00(4K)29K29K
Net Income(29.2M)(16.89M)(267.63M)(251.39M)(127.09M)
Net Margin-112.4%-10758.6%-14729.1%-5898.4%-3492.3%
EPS (Basic)(0.05)(0.03)(25.95)(10.83)(2.78)
EPS (Diluted)(0.05)(0.03)(25.95)(10.83)(2.78)
Weighted Avg Shares578.47M578.47M10.31M23.22M457.57M
Weighted Avg Shares (Diluted)578.47M578.47M10.31M23.22M457.57M

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.